Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev, Boris G
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. [electronic resource] - Oncology 2012 - 117-27 p. digital
Publication Type: Journal Article; Review
1423-0232
10.1159/000339539 doi
Antineoplastic Agents--therapeutic use
Benzenesulfonates--therapeutic use
Cell Differentiation
ErbB Receptors--metabolism
Everolimus
Histone Deacetylases--metabolism
Humans
Immunologic Factors--therapeutic use
Indazoles
Indoles--pharmacology
Molecular Targeted Therapy--methods
Neuroendocrine Tumors--drug therapy
Niacinamide--analogs & derivatives
Pancreatic Neoplasms--drug therapy
Phenylurea Compounds
Pyridines--therapeutic use
Pyrimidines--therapeutic use
Pyrroles--pharmacology
Receptors, Somatostatin--metabolism
Sirolimus--analogs & derivatives
Sorafenib
Sulfonamides--therapeutic use
Sunitinib
TOR Serine-Threonine Kinases--antagonists & inhibitors
Vascular Endothelial Growth Factor A--metabolism
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. [electronic resource] - Oncology 2012 - 117-27 p. digital
Publication Type: Journal Article; Review
1423-0232
10.1159/000339539 doi
Antineoplastic Agents--therapeutic use
Benzenesulfonates--therapeutic use
Cell Differentiation
ErbB Receptors--metabolism
Everolimus
Histone Deacetylases--metabolism
Humans
Immunologic Factors--therapeutic use
Indazoles
Indoles--pharmacology
Molecular Targeted Therapy--methods
Neuroendocrine Tumors--drug therapy
Niacinamide--analogs & derivatives
Pancreatic Neoplasms--drug therapy
Phenylurea Compounds
Pyridines--therapeutic use
Pyrimidines--therapeutic use
Pyrroles--pharmacology
Receptors, Somatostatin--metabolism
Sirolimus--analogs & derivatives
Sorafenib
Sulfonamides--therapeutic use
Sunitinib
TOR Serine-Threonine Kinases--antagonists & inhibitors
Vascular Endothelial Growth Factor A--metabolism